About Medinol
The Medinol Group is Dedicated to the Science of Cardiovascular Intervention
Backed by over 400 patents, the company has delivered over 2,000,000 stents to date and its cutting-edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results.
Medinol’s products constantly stretch the limits of innovation; the scientific spirit that led the company to pioneer the revolutionary NIR stent in 1996 still drives its multidisciplinary team today.
The company is privately-held, and the full scope of its activity – including research, development, quality control, regulatory affairs, clinical trials, manufacturing, marketing, and sales – is conducted in-house.
NIR Stent
Legacy
This breakthrough vastly expanded the patient base suitable for stenting and positioned stenting as the favored treatment over more risky, complex and expensive surgical intervention.
In-line with Medinol’s commitment to proven clinical excellence, NIR stents are some of the most clinically-studied Bare Metal Stents ever produced. Since 1995, NIR and its successors have been examined in over 25 clinical studies involving more than 5000 patients.
Founders
Under Dr. Judith Richter and Dr. Jacob (Kobi) Richter leadership, Medinol fundamentally transformed the interventional cardiology industry through innovation and revolutionary technology. With an extremely cost-efficient manufacturing operation and best-in-class products, Dr. Judith Richter and Dr. Jacob (Kobi) Richter grew Medinol to become a significant international player in the stenting industry, highly reputable for its commitment to promote scientific advances and health.
NIR Legacy of
Innovation
